Macrocytosis may be associated with mortality in chronic hemodialysis patients: A prospective study

BMC Nephrology

Volumn 12, Issue 1, 2011, Pages

  Tennankore, Karthik K ^a   Soroka, Steven D ^a   West, Kenneth A ^a   Kiberd, Bryce A ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; FERRIC HYDROXIDE SUCROSE; FOLIC ACID; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; INSULIN; IRON DEXTRAN; MULTIVITAMIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ANTIANEMIC AGENT; CYANOCOBALAMIN; DRUG DERIVATIVE; ERYTHROPOIETIN; THYROTROPIN;

ADULT; AGED; ARTICLE; CHARLSON AGE COMORBIDITY INDEX; CONTINUOUS VARIABLE; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL VARIABLE; MEAN CORPUSCULAR VOLUME; MEGALOCYTOSIS; MORTALITY; PREVALENCE; PROSPECTIVE STUDY; RATING SCALE; AGE; BLOOD; CHRONIC KIDNEY FAILURE; COMORBIDITY; ERYTHROCYTE DISORDER; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; RENAL REPLACEMENT THERAPY;

AGE FACTORS; AGED; AGED, 80 AND OVER; COMORBIDITY; ERYTHROCYTE INDICES; ERYTHROCYTES, ABNORMAL; ERYTHROPOIETIN; FEMALE; FOLIC ACID; HEMATINICS; HEMOGLOBINS; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; ROC CURVE; THYROTROPIN; VITAMIN B 12;

EID: 79955763341     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-12-19     Document Type: Article

References (38)

1. Iron balance in hemodialysis patients. JW Eschbach JD Cook BH Scribner CA Finch, Ann Intern Med 1977 87 710 713 931207 (Pubitemid 8262908)
2. Recombinant human erythropoietin: Implications for nephrology. JW Eschback JW Adamson, Am J Kidney Dis 1988 11 203 209 3278599 (Pubitemid 18086759)
3. Hemolysis in chronic renal failure. AB Shaw, BMJ 1967 2 213 215 10.1136/bmj.2.5546.213 6023106
4. Megaloblastic hematopoiesis in uremia and in patients on long-term hemodialysis. CL Hampers R Streiff DG Nathan D Snyder JP Merrill, N Engl J Med 1980 276 226 233
5. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. JW Eschbach JC Egrie MR Downing JK Browne JW Adamson, N Engl J Med 1987 316 73 78 10.1056/NEJM198701083160203 3537801 (Pubitemid 17052741)
6. Novel erythropoiesis stimulating protein. IC Macdougall, Semin nephrol 2000 20 375 381 10928340
7. Anemia in hemodialysis patients: variables affecting this outcome predictor. F Madore EG Lowrie C Brugnara NL Lew JM Lazarus K Bridges WF Owen, J Am Soc Nephrol 1997 8 1921 1929 9402095 (Pubitemid 28185451)
8. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. RN Foley PS Parfrey JD Harnett GM Kent DC Murray PE Barre, Am J Kidney Dis 1996 28 53 61 10.1016/S0272-6386(96)90130-4 8712222 (Pubitemid 26231466)
9. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. DL Regidor JD Kopple CP Kovesdy RD Kilpatrick CJ McAllister J Aronovitz S Greenland K Kalantar-Zadeh, J Am Soc Nephrol 2006 17 1181 1191 10.1681/ASN.2005090997 16565261
10. Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial. JH Lau AS Gangji CG Rabbat KS Brimble, Nephrol Dial Transplant 2010 25 4002 4009 10.1093/ndt/gfq330 20530806
11. Challenging the validity of the EPO index. GA Kaysen HG Muller J Ding GM Chertow, Am J Kidney Dis 2006 47 166.e1 166.e13 10.1053/j.ajkd.2005.09.013 (Pubitemid 41828278)
12. Mechanism of increased mortality risk with erythropoietin treatment to higher haematocrit targets. S Fishbane A Besarab, Clin J Am Soc Nephrol 2007 2 1274 1282 10.2215/CJN.02380607 17942772
13. Hematologic aspects of end-stage renal failure. P Zachee J Vermylen MA Boogaerts, Ann Hematol 1994 69 33 40 10.1007/BF01757345 8061105 (Pubitemid 24255449)
14. Hematological profile of chronic kidney disease (CKD) patients in Iran, in pre-dialysis stages and after initiation of hemodialysis. R Afshar S Sanavi J Salimi M Ahmadzadeh, Saudi J Kidney Dis Transpl 2010 21 368 371 20228535
15. Unanticipated favorable effects of correcting iron deficiency in chronic hemodialysis patients. VE Pollak JA Lorch RT Means Jr, J Investig Med 2001 49 173 183 10.2310/6650.2001.34044 11288758 (Pubitemid 32187091)
16. Profile of anemia in chronic renal failure patients: comparison between predialyzed and dialyzed patients at the Division of Nephrology, Department of Internal Medicine, Sanglah Hospital, Denpasar, Bali, Indonesia. K Suega M Bakta TG Dharmayudha JS Lukman K Suwitra, Acta Med Indones 2005 37 190 194 16354939
17. Iron induced increase in red cell size in haemodialysis patients. R Gokal DJ Weatherall C Bunch, Q J Med 1979 48 393 401 542585 (Pubitemid 10200357)
18. Dialysis-induced change in erythrocyte volume: effect on change in blood volume calculated from packed cell volume. SJ Fleming JS Wilkinson C Aldridge RN Greenwood SD Muggleston LR Baker WR Cattell, Clin Nephrol 1988 29 63 68 3359696 (Pubitemid 18060061)
19. Investigations on red cell size distribution histograms in subjects treated by maintenance haemodialysis. PC Bartels PW Helleman JB Soons, J Clin Chem Clin Biochem 1990 28 113 118 2329314 (Pubitemid 20078082)
20. ABC of clinical haematology. Macrocytic anaemias. V Hofbrand D Provan, BMJ 1997 314 430 433 9040391 (Pubitemid 27067807)
21. Practical considerations of recombinant human erythropoietin therapy. EP Paganini D Latham M Abdulhadi, Am J Kidney Dis 1989 14 19 25 2510507 (Pubitemid 19218258)
22. The macrocytic response to erythropoietin stimulation. G Brecher F Stohlman Jr, Erythropoiesis New York and London: Grune and Stratton, Jacobson LO, Doyle M, 2 1962 216 221
23. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. VE Pollak JA Lorch R Shukla S Satwah, BMC Nephrol 2009 10 6 18 10.1186/1471-2369-10-6 19245700
24. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. ME Charlson P Pompei AL Ales CR MacKenzie, J Chron Dis 1987 40 373 383 10.1016/0021-9681(87)90171-8 3558716 (Pubitemid 17055592)
25. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. S Beddhu FJ Bruns M Saul P Seddon ML Zeidel, Am J Med 2000 3 253 260
26. Performance Evaluation of the Coulter LH 750 Hematology Analyzer. T Fernandez LB Domack D Montes R Pineiro E Landrum E Vital, Lab Hematol 2001 7 217 228 (Pubitemid 33100777)
27. Final Report: The Canadian Enhancement of ICD-10 (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision). http://www.cihi.ca
28. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. A Besarab WK Bolton JK Browne JC Egrie AR Nissenson DM Okamoto SJ Schwab DA Goodkin, N Engl J Med 1998 339 584 590 10.1056/NEJM199808273390903 9718377 (Pubitemid 28385655)
29. The normal hematocrit cardiac trial revisited. DA Goodkin, Semin Dial 2009 22 495 502 10.1111/j.1525-139X.2009.00620.x 19650856
30. Clinical significance of a high mean corpuscular volume in nonanemic patients. KL Thong SA Hanley JA McBride, CMAJ 1977 117 908 910 (Pubitemid 8231299)
31. Unexplained macrocytosis in elderly patients. MY Mahmoud M Lugon CC Anderson, Age Ageing 1996 25 310 312 10.1093/ageing/25.4.310 8831877 (Pubitemid 26245281)
32. How Erythropoietin Affects Bone Marrow of Uremic Patients. A Sikole A Stojanovic M Polenakovic G Petrusevska S Sadikario R Saso M Jovanovski, Am J Nephrol 1997 17 128 136 10.1159/000169086 9096443 (Pubitemid 27141903)
33. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). DA Goodkin JL Bragg-Gresham KG Koenig RA Wolfe T Akiba VE Andreucci A Saito HC Rayner K Kurokawa FK Port PJ Held EW Young, J Am Soc Nephrol 2003 14 3270 3277 10.1097/01.ASN.0000100127.54107.57 14638926 (Pubitemid 37509303)
34. Key comorbid conditions that are predictive of survival among hemodialysis patients. D Miskulin J Bragg-Gresham BW Gillespie F Tentori RL Pisoni H Tighiouart AS Levey FK Port, Clin J Am Soc Nephrol 2009 4 1818 1826 10.2215/CJN.00640109 19808231
35. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. WF Owen Jr NL Lew Y Liu EG Lowrie JM Lazarus, N Engl J Med 1993 329 1001 1006 10.1056/NEJM199309303291404 8366899 (Pubitemid 23307908)
36. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. AR Qureshi A Alvestrand JC Divino-Filho A Gutierrez O Heimburger B Lindholm J Bergstrom, J Am Soc Nephrol 2002 13 Suppl 1 128 36
37. Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study. Y Hasuike H Nonoguchi M Tokuyama M Ohue T Nagai M Yahiro M Nanami Y Otaki T Nakanishi, Clin Exp Nephrol 2010 14 349 355 10.1007/s10157-010-0288-x 20467772
38. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. K Kalantar-Zadeh BR Don RA Rodriguez MH Humphreys, Am J Kidney Dis 2001 37 564 572 10.1016/S0272-6386(01)80014-7 11228181 (Pubitemid 32195296)